JP2558208B2 - インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤 - Google Patents

インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤

Info

Publication number
JP2558208B2
JP2558208B2 JP4506077A JP50607793A JP2558208B2 JP 2558208 B2 JP2558208 B2 JP 2558208B2 JP 4506077 A JP4506077 A JP 4506077A JP 50607793 A JP50607793 A JP 50607793A JP 2558208 B2 JP2558208 B2 JP 2558208B2
Authority
JP
Japan
Prior art keywords
indan
group
melting point
kbr
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP4506077A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06510787A (ja
Inventor
清史 吉田
美明 山路
忠 栗本
隆一 佐藤
元樹 鳥塚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeria Pharmaceutical Co Ltd
Original Assignee
Zeria Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co Ltd filed Critical Zeria Pharmaceutical Co Ltd
Priority to JP4506077A priority Critical patent/JP2558208B2/ja
Publication of JPH06510787A publication Critical patent/JPH06510787A/ja
Application granted granted Critical
Publication of JP2558208B2 publication Critical patent/JP2558208B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP4506077A 1991-03-01 1992-02-28 インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤 Expired - Fee Related JP2558208B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4506077A JP2558208B2 (ja) 1991-03-01 1992-02-28 インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP3-57619 1991-03-01
JP5761991 1991-03-01
US760,552 1991-09-16
JP4506077A JP2558208B2 (ja) 1991-03-01 1992-02-28 インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤
US876,887 1992-04-30

Publications (2)

Publication Number Publication Date
JPH06510787A JPH06510787A (ja) 1994-12-01
JP2558208B2 true JP2558208B2 (ja) 1996-11-27

Family

ID=13060895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4506077A Expired - Fee Related JP2558208B2 (ja) 1991-03-01 1992-02-28 インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤

Country Status (12)

Country Link
US (1) US5409956A (enExample)
EP (1) EP0589037B1 (enExample)
JP (1) JP2558208B2 (enExample)
KR (1) KR0184701B1 (enExample)
AT (1) ATE138645T1 (enExample)
AU (1) AU651182B2 (enExample)
CA (1) CA2105067C (enExample)
DE (1) DE69211133T2 (enExample)
DK (1) DK0589037T3 (enExample)
ES (1) ES2090611T3 (enExample)
GR (1) GR3020106T3 (enExample)
WO (1) WO1992015558A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2099743A1 (en) * 1992-07-02 1994-01-03 Akihiko Ishida Pyridazinone derivatives and processes for preparing the same
US5739132A (en) * 1992-07-02 1998-04-14 Tanabe Seiyaku Co., Ltd. Pyridazinone derivatives and processes for preparing the same
CA2139088A1 (en) * 1993-12-28 1995-06-29 Akihiko Ishida Indane derivatives, processes for preparing the same and synthetic intermediate of the same
US6017953A (en) * 1993-12-28 2000-01-25 Allergan Sales, Inc. Thromboxane ligands
CA2138812A1 (en) * 1993-12-28 1995-06-29 Akihiko Ishida Indane derivative and processes for preparing the same
JPH0859458A (ja) * 1994-08-25 1996-03-05 Zeria Pharmaceut Co Ltd インダン誘導体を含有する高脂血症治療剤
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
DE19604191A1 (de) * 1996-02-06 1997-08-07 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO1998038156A1 (en) 1997-02-27 1998-09-03 Takeda Chemical Industries, Ltd. Amine compounds, their production and use as amyloid-beta production inhibitors
FR2760235B1 (fr) * 1997-02-28 1999-04-09 Adir Nouveaux derives de benzenesulfonylamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN100349872C (zh) 2000-04-03 2007-11-21 武田药品工业株式会社 制备胺衍生物的方法
WO2002002119A1 (en) * 2000-06-29 2002-01-10 Smithkline Beecham Corporation Fatty acid synthase inhibitors
DE10229180A1 (de) * 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
CN103539709B (zh) * 2013-03-22 2015-11-25 湖北生物医药产业技术研究院有限公司 N-(-1-氢-茚-1-基)磺酰胺类化合物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623944A1 (de) * 1986-07-16 1988-02-11 Thomae Gmbh Dr K Neue benzolsulfonamido-indanylverbindungen, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5190975A (en) * 1987-11-18 1993-03-02 Tanabe Seiyaku Co., Ltd. Indan derivatives used for treating thromboses or asthma
IL88314A (en) * 1987-11-18 1994-05-30 Tanabe Seiyaku Co Sulphonylamino indane derivatives, their preparation and pharmaceutical compositions containing them
FR2645537B1 (fr) * 1989-04-05 1994-03-04 Fabre Medicament Pierre Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
EP0589037A4 (enExample) 1994-04-27
CA2105067A1 (en) 1992-09-02
AU651182B2 (en) 1994-07-14
KR0184701B1 (en) 1999-05-15
WO1992015558A1 (fr) 1992-09-17
DE69211133D1 (en) 1996-07-04
ATE138645T1 (de) 1996-06-15
CA2105067C (en) 2002-05-14
AU1338492A (en) 1992-10-06
EP0589037A1 (en) 1994-03-30
KR930703249A (ko) 1993-11-29
US5409956A (en) 1995-04-25
DK0589037T3 (da) 1996-09-16
GR3020106T3 (en) 1996-08-31
DE69211133T2 (de) 1996-10-31
EP0589037B1 (en) 1996-05-29
JPH06510787A (ja) 1994-12-01
ES2090611T3 (es) 1996-10-16

Similar Documents

Publication Publication Date Title
JP2558208B2 (ja) インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤
EP0472449B1 (fr) Nouveaux sulfonamides substitués procédés de préparation et médicaments les contenant
OA12631A (fr) Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés.
JPWO2000015603A1 (ja) ベンゼン誘導体及びその医薬用途
KR101194968B1 (ko) Ｐｔｐ 1-ｂ 저해제로서의 1,1’-(1,2-에틴디일)비스-벤젠유도체
RU2345063C2 (ru) Сульфоновые кислоты, производные указанных кислот и содержащие их фармацевтические композиции
HU224354B1 (hu) 2-Aminoindán-származékok alkalmazása és az ezeket tartalmazó gyógyszerkészítmények
KR950004046B1 (ko) 인단 유도체 및 그의 제조방법
TWI303628B (en) 5-amidino-2-hydroxybenienesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
EP0430459B1 (en) Tetrahydronaphthalene derivatives and preparation thereof
JPH0859458A (ja) インダン誘導体を含有する高脂血症治療剤
JPH0753505A (ja) ベンゼンスルホンアミド誘導体及びその用途
JPH02184662A (ja) グリシン誘導体
JPWO1992015558A1 (ja) インダン誘導体及び該化合物を含有するトロンボキサン拮抗剤
AU7528098A (en) New nitromethyl ketones, process for preparing them and compositions containing them
CN1036267C (zh) 氨基取代的苯甲酰胍的制备方法
JPH0372420A (ja) トロンボキサンａ↓２拮抗薬
JPH01175962A (ja) フェニル酢酸誘導体
EP0946503A1 (fr) Derives du nitromethylthiobenzene comme inhibiteurs de l'aldose reductase
JPH05194370A (ja) スルホンアミド誘導体
JPH068275B2 (ja) フェノキシ酢酸誘導体
JPWO2001016091A1 (ja) ビスシクロプロパンカルボン酸アミド化合物およびその医薬用途
JPH0372419A (ja) トロンボキサンａ↓２拮抗剤
JPH05262736A (ja) フェノキシ酢酸誘導体
JPH03128317A (ja) トロンボキサンａ↓２拮抗剤

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees